Ovid Therapeutics
OVID
48 hedge funds and large institutions have $49.8M invested in Ovid Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 10 closing their positions.
271% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 7
2% less funds holding
Funds holding: 49 → 48 (-1)
3.15% less ownership
Funds ownership: 31.8% → 28.65% (-3.1%)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
35% less capital invested
Capital invested by funds: $77.2M → $49.8M (-$27.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.39M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$685K |
| 3 |
Jennison Associates
New York
|
+$588K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$538K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$481K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$6.64M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.21M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.78M |
| 4 |
CC
Casdin Capital
New York
|
-$1.58M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
51
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.78M | -180,674 | Closed |
|
|
CC
52
Casdin Capital
New York
| – | -$1.58M | -160,000 | Closed |
|
53
Victory Capital Management
San Antonio,
Texas
| – | -$1.04M | -105,470 | Closed |
|
|
PAM
54
Panagora Asset Management
Boston,
Massachusetts
| – | -$99K | -10,011 | Closed |
|
|
TA
55
Teachers Advisors
New York
| – | -$60K | -6,063 | Closed |
|
56
Parallax Volatility Advisers
San Francisco,
California
| – | -$7K | -756 | Closed |
|
|
DCM
57
Delpha Capital Management
New York
| – | -$3K | -314 | Closed |
|
58
UBS Group
Zurich,
Switzerland
| – | -$2K | -227 | Closed |
|
OVID Hedge Fund Activity: Q1 2018 in Review
48 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2018, worth a combined $49.8M — down 35% from $77.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of OVID and 9 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $2.39M. The largest seller was Putnam Investments, exiting entirely with an estimated $6.64M sold.
- 48 institutional investors held Ovid Therapeutics (OVID) as of Q1 2018, down from 49 in Q4 2017.
- Funds reported $49.8M of Ovid Therapeutics stock for Q1 2018, down 35% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q1 2018 and 10 closed out, a net change of -1 holder.
- The largest Ovid Therapeutics buyer in Q1 2018 was BlackRock, an estimated $2.39M added.
- The largest Ovid Therapeutics seller in Q1 2018 was Putnam Investments, an estimated $6.64M sold.
Based on aggregated 13F filings for Q1 2018.